Scientific Programme

“Innovation – Prevention – Preparedness”

The ERA 2022 Congress in Paris will take place from May 19 to 22, 2022 as a hybrid event, thus being both live and virtual, with speakers, chairs and delegates attending live and remotely.

The Congress programme is now online and guarantees, both live and virtual, top-quality presentations, and a close interaction with the attendees.

For any queries regarding the programme, please send an e-mail to program@era-online.org

Programme at a glance

The preliminary programme is now availble for download.

Tracks

Discover the major topics of the 2022 ERA Congress.

PLENARY LECTURES

1. Equity, sustainability, and ethics in kidney health
Valerie Luyckx, Switzerland

2. PCSK9: a journey of discovery from genetics to clinical trials
Catherine Boileau, France

3. Bioelectronic Medicine, hypertension and inflammation
Tracey Kevin, USA

0 - INSTITUTIONAL

Symposium 0.1
LATE BREAKING CLINICAL TRIALS
Chairs: Maria Soler  & Danilo Fliser
waiting confirmation from the invited speakers

Symposium 0.2
ERA-EDTA REGISTRY
Chairs: Kitty J. Jager & Alberto Ortiz

1. Results of the European transplant survey: initiatives and barriers affecting kidney transplant rates
Rianne Boenink, Netherlands

2. Mortality due to malignancies in children starting kidney replacement therapy after cancer therapy
Henna Puusaari, Finland

3. Effect of dialysis initiation on health-related quality of life and symptoms in older patients
Esther de Rooij, Netherlands

Symposium 0.2.1
WHY NEPHROLOGY NEEDS ADVANCED STATISTICAL METHODS
Chairs: Ivan Rychlik & Vivek Jha

1. Target Trial Emulation: Implications for outcome studies on timing of dialysis initiation
Edouard Fu, Netherlands

2. Target Trial Emulation: Implications for transplant survival studies
Vianda Stel, Netherlands

3. Joint Models – Applications in nephrology
Nick Chesnaye, Netherlands

Symposium 0.3
ASN Highlights
Chairs: waiting confirmation from the invited chairs

1. AKI
Anitha Vijayan, USA

2. General Nephrology and CKD
Joachim H. Ix, USA

3. Hypertension
Tara I. Chang, USA

Symposium 0.4
2021 PEARLS OF NDT AND CKJ
Chairs: Denis Fouque & Maria Soler

1. NDT
Marlies Ostermann, UK
Hans-Joachim Anders, Germany

2. CKJ
Roser Torra, Spain
Will Herrington, UK

Symposium 0.5
JOINT SYMPOSIA ERA- SFNDT ARTIFICIAL INTELLIGENCE IN NEPHROLOGY
Chairs: Maryvonne Hourmand & Jadranka Buturović-Ponikvar

1. From the database to the clinic
Alexandre Loupy, France
Pierre-Antoine Gourraud, France

2.Artificial intelligence in nephropathology:
Vincent Vuiblet, France

3. Connected stools in nephrology
Patrick Jourdain, France

Symposium 0.6
BEYOND THE BASICS OF SOCIAL MEDIA USE: ADVANCED SOCIAL MEDIA TOOLS FOR EDUCATION
Chairs: Kate Stevens  & Alexander Rosenkranz

1. Creating and distributing Visual Abstracts
Michelle Lim, UK

2. Polarization: Morphology of Renal Networks on Twitter
Tejas Desaim, USA

3. Generating data from Social Media: a tool to be taken seriously?
Kate Stevens, UK

Symposium 0.7
NEPHROLOGY PEARLS
Chairs: Christoph Wanner  & Serhan Z. Tuglular

1. Basic Science and Translational Nephrology
Marianne Verhaar, Netherland

2. Epidemiology and Clinical Nephrology
Kitty Jager, Netherland

3. ESKD and Dialysis
Giovanni Gambaro, Italy

4. Kidney Transplantation
Andreas Kronbichler, United Kingdom

MINI LECTURES

ML 0.1 EKHA AND THE DECADE OF THE KIDNEY
Ray Vanholder, Belgium

ML 0.2 PROMS CAN REPLACE TRADITIONAL OUTCOMES IN CLINICAL TRIALS? WHAT IS MORE IMPORTANT Hemoglobin value or patient’s tiredness?
Giovanni Tripepi, Italy

ML 0.3 GENDER AND NEPHROLOGY
Sofia Ahmed, Canada

1 - FLUID & ELECTROLYTES, TUBULAR TRANSPORT, RENAL PHYSIOLOGY

Symposium 1.1
NOVEL TECHNIQUES – NOVEL INSIGHTS INTO KIDNEY FUNCTION
Chairs: waiting confirmation from the invited chairs

1. Urinary extracellular vesicles and tubular transport
Ewout J Hoorn, Netherlands

2. Pathogenic evaluation of synonymous COL4A5 variants in X-linked Alport syndrome using a minigene assay.
Tomoko Horinouchi, Japan

3. 2-Photon microscopy and Cell-fate tracking reveals novel repair mechanisms in kidney injury
Ina Schiessl, Denmark

Symposium 1.2
PLASTICITY OF RENAL CELLS
Chairs: Alberto Ortiz & Robert Fenton

1. The plasticity of renin-producing cells
Armn Kurtz, Germany

2. The different facets of Myofibroblasts in kidney
Rafael Kramann, Germany

3. Proximal tubule dysfunction in Glycogen Storage Disease
Francesco Trepiccione, Italy

Symposium 1.3
TUBULAR TRANSPORT
Chairs: Carsten Wagner & Sandrine Florquin

1. Potassium channels controlling tubular functions
Richard Warth, Germany

2. Mitochondrial function and diversity along the nephron
Andrew Hall, Switzerland

3. Oxalate handling in health and disease-crosstalk gut and kidney
Felix Knauf, Germany

Symposium 1.4
PHYSIOLOGY OF PODOCYTES: CLINICAL IMPLICATIONS
Chairs: Rachel Lennon & Marc Vervloet

1. Super-resolution microscopy meets kidney research and diagnosis
Nicole Endlich, Germany

2. Vitamin D3 influences the differentiation of podocytes in situ and in vitro
Tim Lange, Germany

3. Podocyte lipid metabolism
Catherine Meyer-Schwesinger, Germany

MINI LECTURES

ML 1.1 MITOCHONDRIAL HOMEOSTASIS IN PROXIMAL TUBULAR CELLS
Santiago Lamas, Spain

ML 1.2 RENAL METABOLISM AND HYPERTENSION
Mingyu Liang, USA

ML 1.3 KIDNEY INTERCALATED CELLS IN HEALTH AND DISEASE
Dominique Eladari, Paris

ML 1.4 REPROGRAMMING TUBULAR CELLS
Soeren Lienamp, Switzerland

ML 1.5 RENAL GLUCONEOGENESIS AS A NOVEL TARGET TO REDUCE MORTALITY IN AKI
Sophie de Seigneux, Switzerland

ML 1.6 ZEBRAFISH LARVAE TO STUDY AND TREAT GLOMERULAR DISEASES
Anna Iervolino, Italy

2 - HEREDITARY DISORDERS, DEVELOPMENT, PREGNANCY, PAEDIATRIC NEPHROLOGY

Symposium 2.1
DIGNOSTICS AND THERAPEUTIC ADVANCES IN PEDIATRIC NEPHROLOGY
Chairs: Emilie Cornec Le Gall & Nine Knoers

1.Novel immunosuppression strategies in kidney transplantation
Lars Pape, Germany

2.Innovative therapies for nephrotic syndrome
Marina Vivarelli, Italy

3.Mitochondrial diseases from childhood to adulthood
Fatih Ozaltin, Turkey

Symposium 2.2
CHALLENGES IN PEDIATRIC NEPHROLOGY
Chairs: Peter Barany & Elena Levtchenko

1. Rewired: neurocognitive function in CKD
Jaap Groothoff, Netherlands

2. Transition adolescent with CKD to adult clinics
Gema Ariceta, Spain

3. Isotope diagnostics to improve CKD-MBD management
Rukshana Shroff, UK

Symposium 2.3
HOW TO OPTIMALLY PREVENT PROGRESSION IN ADPKD.
Chairs: Roser Torra & Albert Ong

1. Lifestyle interventions
Esther Meijern, Netherlands

2. How to improve tolerability of tolvaptan
Ron Gansevoort, Netherlands

3. Updated ERA-EDTA WGIKD / ERKNet position statement which ADPKD patients to prescribe tolvaptan
Roman Muller, Germany

Symposium 2.4
BRIDGING THE GAP BETWEEN GENETICS AND NEPHROLOGY WORLDS: LET’S ALL BECOME NEPHROGENETICISTS
Chairs: Rukshana Shroff & Franz Schaefer

1. How the genomics England consortium changed nephrogenetics in England.
Daniel Gale, UK

2. Genetic-first approaches in ESKD of unknown significance
Laurent Mesnard, France

3. What about the kids: practical aspects of care for children at risk of genetic disease that all adult nephrologists should know.
Djalila Mekali, Belgium

Symposium 2.5
PREGNANCY AND THE KIDNEY
Chairs: Liz Lightstone & Jolanta Malysko

1. Renal and pregnancy outcomes in advanced CKD patients
Liz Lightstone, UK

2. Effect of pregnancy on eGFR slope and predictors of pregnancy outcomes in kidney transplantation: a national cohort study
Marleen C. van Buren, Netherlands

3. Adverse pregnancy outcomes and long-term maternal kidney disease
Peter Barrett, Ireland

Symposium 2.6
INHERITED CYSTIC AND TUBULOINTERSTITIAL NEPHROPATHIES: NEW GENES, NEW MECHANISMS, NEW THERAPIES
Chairs: Marianne Verhaar & Ron Gansevoort

1. The expanding genetic spectrum of polycystic kidney and liver diseases
Emilie Cornec-Le Gall, France

2. Unravelling diseases mechanisms in ciliopathies
Sophie Saunier, Paris

3. New therapeutic approaches for toxic proteinopathies, the example of ADTKD-MUC1
Moran Dvela-Levitt, Israel

MINI LECTURES

ML 2.1 GROWING KIDNEYS: A PARTY TRICK OR REALITY?
Adrian Woolf, UK

ML 2.2 CHILDHOOD CANCER AND RISK OF ESKD
Asaf Vivante, Israel

ML 2.3 PERSONALISED DIAGNOSIS AND CKD PREDICTION IN GENETIC TUBULAR DISORDERS
Francesca Becherucci, Italy

ML 2.4 PREIMPLANTATION TESTING IN MONOGENIC KIDNEY DISEASE / GENETICS-FIRST APPROACH IMPROVES DIAGNOSTICS OF ESKD PATIENTS
Albertien Van Eerde, Netherlands

3 - GLOMERULAR DISEASES & GENERAL CLINICAL NEPHROLOGY

Symposium 3.1
INNOVATIONS IN PATHOLOGY TO SUPPORT NEPHROLOGISTS
Chairs: Ingeborg M. Bajema & Jan Ulrich Becker

1. Remote renal pathology counseling: Opportunities for the clinician
Helen Liapis, Greece

2. Digital Data-Driven Kidney Pathology Assessment
Arvydas Laurinavicius, Lithuania

3. Artificial intelligence-augmented digital nephropathology
Peter Boor, Germany

Symposium 3.2
GENETICS PLUS X: INNOVATION FROM COMBINING TECHNOLOGIES
Chairs: Albertien van Eerde & John Sayer

1. Combining exome sequencing with reverse phenotyping in steroid-resistant nephrotic syndrome
Francesca Becherucci, Italy

2. Engeerinng patient-derived tissues for studying kidney diseases and testing drugs
Christodoulos Xinaris, Cyprus

3. Combining exome sequencing with urinary metabolomics to unravel inborn errors of metabolism.
Anna Köttgen, Germany

Symposium 3.3
NEW AVENUES IN LUPUS NEPHRITIS
Chairs: Eleni Frangou & Vladimir Tesar

1. Monogenic lupus nephritis. When to check, how to check, and what to do?
Alexandre Belot, France

2. 10 reasons why I rebiopsy my patients with lupus nephritis
Iva Gunnarsson, Swedem

3. How to predict lupus nephritis non-invasively
Eleni Frangou, Cyprus

Symposium 3.4
INNOVATIVE TECHNOLOGIES PROVIDING INNOVATIVE INSIGHTS: KIDNEY REMODELLING UPON INJURY
Chairs: Martin De Borst & Beatriz Sanchez Alamo

1. Single cell RNA sequencing of the human kidney: Identifying new drug targets for kidney fibrosis.
Christian Kuppe, Germany

2. Clonal lineage tracing: The glomerular crescent in RPGN is a monoclonal lesion that responds to clone-directed therapy
Paola Romagnani, Italy

3. Tissue proteomics to monitor stress responses in the kidney
Markus Rinschen, Aarhus, Denmark

Symposium 3.5
ANCA-ASSOCIATED KIDNEY VASCULITIS ACROSS LIFETIME
Chairs: Andreas Kronbichler & Kerstin Westman

1. Pathophysiology of ANCA-associated vasculitis: an update
David Jayne, UK

2. ANCA-associated kidney vasculitis in childhood
Augusto Vaglio, Italy

3. ANCA-associated Kidney vasculitis in adults and in the elderly
Maria Weiner, Sweden

Symposium 3.6
BRIDGING THE GAPS BETWEEN BASIC SCIENCE AND HUMAN TRIALS FOR KIDNEY HEALTH INTERVENTIONS
Chairs: Hans Joachim Anders & Rosanna Coppo

1 Translational research – bridging the gaps between animal studies and human trials for kidney health interventions (drugs)
Agnes Fogo, USA

2. Pathology of interferon-mediated damage
Ingeborg Bajema, The Netherlands

3. The clinic of interferon-mediated damage from viral to autoimmune nephropathies
Giovanni Maria Rossi, Parma

MINI LECTURES

ML 3.1 COMPLEMENT INHIBITION IN IGA NEPHROPATHY
Rosanna Coppo, Italy

ML 3.2 A FAREWELL TO THE CONCEPT OF INDUCTION AND MAINTENANCE THERAPY OF LUPUS NEPHRITIS
Hans-Joachim Anders, Germany

ML 3.3 ASSAYS FOR ANTI-GBM ANTIBODIES AND DETECTION PROBLEMS
Elena Csernok, Germany

ML 3.4 CLINICAL APPLICATION OF MICRORNAS IN GLOMERULAR DISEASE
Jonathan Barratt, UK

ML 3.5 THE ROLE OF SGLT2 INHIBITION IN HEART FAILURE: WHAT CAN NEPHROLOGISTS LEARN FROM CARDIOLOGISTS?
Nikolaus  Marks, Germany

ML 3.6 GWAS IN GLOMERULAR DISEASE AND ITS CONTRIBUTION TO THE UNDERSTANDING OF THE PATHOGENESIS AND IDENTIFICATION OF NEW THERAPEUTIC TARGETS
Matt Sampson, USA

ML 3.7 ABOUT THE GBM AND ANTI-GBM DISEASE
Emmanuelle Plaisier, Paris

ML 3.8 TREATMENT DURATION AND EFFICACY IN C3 GLOMERULOPATHY
Fernando Caravaca-Fontán, Spain

4 - CKD - PATHOPHYSIOLOGY, EPIDEMIOLOGY, PREVENTION, PROGRESSION, AGEING

Symposium 4.1
RENAL AND CARDIAC PROTECTION IN DIABETIC AND NON-DIABETIC CKD
Chairs: Maria Soler & Davide Bolignano

1. SGLT2 inhibitors: from bench to bedside for patients with cardiorenal disease
Daniël van Raalte, Netherlands

2. Novel mineralocorticoid receptors antagonists: an update of mechanisms and recent trials
Frederik Persson, Copenhagen

3. New kidney protective drugs: how do they impact the guidelines?
Paola Fioretto, Italy

Symposium 4.2
CACHEXIA OR PROTEIN ENERGY WASTING: WHAT IS NEW IN CKD?
Chairs: Denis Fouque & Carla Avesani

1. Time to abandon the restriction of fruits and vegetables in patients with chronic kidney disease?
JJ Carrero, Sweden

2. The role of browning in CKD cachexia
Laetitia Koppe, France

3. Intramuscle fat infiltration in CKD: a marker related to muscle quality, muscle strength and sarcopenia
Carla Avesani, SWE

Symposium 4.3
IS MICROBIOTA RESPONSIBLE FOR THE UREMIC TOXICITY?
Chairs: Peter Stenvinkel & Lucia Del vecchio

1. The kidney is responsible for toxins accumulation
Gret Glorieux Ghent, Belgium

2. The microbiota is responsible for toxins production
Sandra Wagner, France

3. Nutrients regulate the microbiota post translational activity and toxin production
Wendy Garrett, Boston

Symposium 4.4
DRUG DISCOVERY AND REPURPOSING
Chairs: Ziad Massy & Lisbet Brandi

1.Drug repurposing: From kidney diseases to COVID-19
Anna Greka, USA

2. RNA therapeutics for rare diseases: hyperoxaluria and beyond
Justine Bacchetta, France

3. Mechanism and reversal of drug-induced nephrotoxicity on a chip
Cristina Podrini, Italy

Symposium 4.5
AGEING IN CKD
Chairs: Goce Spasovski & Beatriz Fernandez Fernandez

1. Ageing biomarkers in CKD: time for rejuvenation?
Katrien De Vusser, Belgium

2. The road to healthy ageing
Paul Shiels, Scotland

3. Targeting the uremic phenotype in CKD: is food as medicine option?
Denise Mafra, Scotland

Symposium 4.6
PHOSPHATE IN CKD FROM BENCH TO BEDSISDE
Chairs: Amaryllis Van Craenenbroeck & Juan Jesus Carrero

1. Consequences of phosphate meeting cholesterol
Xiong Z. Ruan, UK

2. Targeting NaPi-IIb for hyperphosphatemia in CKD Patients – The Dead End?
Mugurel Apetrii, Romania

3. Intestinal phosphate binders to reduce cardiovascular
Nigel Toussaint, Australia

Symposium 4.7
OMICS AND KIDNEY OUTCOMES
Chairs: Luca De Nicola & Lucile Mercadal

1. Genomics
Cristian Pattaro, Italy

2. Proteomic
Julie Klein, France

3. Metabolomic
Belen Ponte, Switzerland

Symposium 4.8
PROGRESSION IN CKD: EARLY DETECTION AND TARGETED PREVENTION
Chairs: Tilman B. Drüeke & Martina Guthoff

1. Diabetic kidney disease – early detection and subsequent intervention for delaying the progression
Goce Spasovski, Greece

2. Acute Kidney Injury in Patients with Chronic Kidney Disease: is an adequate prevention possible?
Mustafa Arici, Turkey

3. Prevention of CKD progression – news in the traditional and imaging factors
Francesca Mallamaci, Italy

Symposium 4.9
MECHANISMS OF HYPERTENSION REVISITED: IMPLICATIONS FOR DIAGNOSIS AND MANAGEMENT
Chairs: Pieter Evenepoel & Dorothea Nitsch

1. Fibromuscular dysplasia: from a rare disease to a frequent clinical suspicion?
Alexandre Persu, Belgium

2. Renal denervation in patients with CKD: current evidence and future perspectives
Roland Schmieder, Germany

3. Blood pressure variability in CKD: from diagnosis to treatment
Jong Hyun Jhee, Korea

Symposium 4.10
TARGETING MR OVERACTIVATION WITH FINERENONE: A NOVEL APPROACH TO KIDNEY AND CARDIOVASCULAR PROTECTION IN PATIENTS WITH CKD AND T2D
Chairs: Cristoph Wanner & Paola Fioretto

1. Welcome and introductions

2. Unmet need CKD in T2D: Targeting mineralocorticoid receptor (MR) overactivation
David Cherney, Canada

3. FIDELITY – Cardiorenal outcomes across the spectrum of CKD in T2D
George Bakris, USA

4. Safety and considerations for optimising patient outcomes
Katherine Tuttle, USA

5. Implications of key subgroup analyses from the trial programme
Peter Rossing, Danmark

6. Clinical consequences of the findings – UACR as a Cardiovascular and kidney outcomes risk factor
Rajiv Agarwal, USA

Q&A
All

Summary and close
Chair

MINI LECTURES

ML 4.1 COVID VACCINATION UPDATE IN KIDNEY DISEASE PATIENTS
Michelle Willicombe, UK

ML 4.2 THE DIFFERENT FACES OF ‘THE’ RENAL FUNCTION: LOOKING BEYOND THE NORMALIZED EGFR FOR DRUG DOSING, PROGNOSTICATION AND FOLLOW UP.
Maarten Rookmaaker, Netherland

ML 4.3 OXYGEN BIOLOGY IN THE CKD PATIENTS
Masaomi Nangaku, Japan

5 - KIDNEY FAILURE, KIDNEY FUNCTION REPLACEMENT THERAPIES

Symposium 5.1
CKD ARRHYTMIAS AND ANTICOAGULATION
Chairs: Mario Cozzolino & Nada Dimkovic

1. Arrhythmias in CKD and ESRD and their relation to sudden death
Karolina Szummer, Sweden

2. Anticoagulation in patients with CKD and ESKD
Marie Evans, Sweden

3 Sudden death in patients with ESKD
Nobuhiko Joki, Japan

Symposium 5.2
ASSESSING QUALITY OF DIALYSIS DELIVERY
Chairs: Edwina Brown & Carlo Basile

1. Are we aware of the extent to which the quality of dialysis depends on vascular access?
Jose Ibeas, Spain

2. Goal directed dialysis: individualising the prescription – can HD learn from PD?
Albert Power, UK

3. Generic or individualised patient outcome measures?
Esmee M. van der Willik, Netherlands

Symposium 5.3
EXPANSION OF HOME THERAPIES IN EUROPE: DESIRABLE AND POSSIBLE?
Chairs: Nicola Matthews & Tamara Jemcov

1. Why does use of home therapies vary across Europe?
Maria Slon Roblero, Spain

2. Variability of home therapies use in UK units: early results from the Inter-CEPt study
Simon Davies, UK

3. Does access to assisted PD increase use of PD
Anita van Eck van der Sluijs, Netherlands

Symposium 5.4
SUPPORTING NEEDS OF OLDER FRAIL PEOPLE CONSIDERING DIALYSIS
Chairs: Andrew Davenport & Liliana Garneata

1. Devloping a supportive assisted CAPD programme
Edwina Brown, UK

2. Why does cognitive function decline and what can be done about it
Dawn F Wolfgram, USA

3. Benefits of conversations about ceilings of care
Monika Lichodziejewska-Niemierko, Poland

Symposium 5.5
CKD-MBD IN ESKD – TRADITIONAL AND NOVEL APPROACHES
Chairs: Halima Resic & Ligia Petrica

1. Evaluation of bone fracture risk in CKD
Hanne Skou Jorgensen, Denmark

2. Klotho and/or FGF23: ready to measure both?
Marc Vervloet, Netherlands

3. VDR and CaSR activation as treatment options
Mario Cozzolino, Italy

Symposium 5.6
CHOICE OF KRT
Chairs: Olof Heimbürger & Maria Haller

1. Transition between KRT modalities
Antoine Lanot, France

2. Shared decision making in KRT
Nicola Thomas, UK

3. Incremental hemodialysis
Giorgina Piccoli, Italy

Symposium 5.7
THE CONNECT PROJECT: COGNITIVE DECLINE IN NEPHRO-NEUROLOGY: EUROPEAN COOPERATIVE TARGET
Chairs: Elena Zakharova & Sanjin Racki

1. Evidence on albuminuria as a risk factor for dementia
Gaye Hafez, Turkey

2. How the kidney may affect brain cognitive function
Giovambattista Capasso, Italy

3. Cognitive function in dialytic and transplanted patients
Casper Franssen, Netherlands

MINI LECTURES

ML 5.1 EMBEDDING NEEDS OF OLDER PEOPLE INTO ROUTINE MANAGEMENT OF ESKD
Andrew Nixon, UK

ML 5.2 ANEMIA AND IRON UPDATE FROM KDIGO
Jolanta Malyszko, Poland

ML 5.3 CLINICAL TESTING FOR COGNITIVE FUNCTION IN CKD PATIENTS
Marion Pepin, France

ML 5.4 CHALLENGES IN TRAINING NEPHROLOGISTS FOR HOME ORIENTED CARE
Jernej Pajek, Slovenia

6 - TRANSPLANTATION AND IMMUNOLOGY

Symposium 6.1
ONCONEPHROLOGY
Chairs: Smaragdi Marinaki & Rainer Oberbauer

1. Immune Checkpoint Inhibitor Therapy in solid organ recipients
Maria Soler, Spain

2. Haematological malignancies post transplant – what’s new?
Ben Sprangers, Belgium

3. Can Nephrologist improve the Outcomes of Cancer patients?
Mariadelina Simeoni, Italy

Symposium 6.2
IMMUNOCOMPETENCE IN RENAL TRANSPLANTATION
Chairs: Umberto Maggiore & Marta Crespo

1. Torque-teno virus and kidney transplantation: can we tailor immunosuppression?
Gregor Bond, Austria

2. Steering transplant immunosuppression by virus-specific T Cells
Thurid Ahlenstiel-Grunow, Germany

3. CMV disease in transplantation
Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention

Symposium 6.3
TRANSPLANTATION BASIC SCIENCE
Chairs: Daniel Abramowicz & Maria C. Haller

1.Single cell technology; the role of the immune cell atlas in renal transplantation
Menna Clatworthy, UK

2.Artificial Intelligence: a simple approach to a complex issue or Artificial Intelligence: from bench to bedside or How to talk to molecular biologists?
Germaine Wong, Australia

3. ABMR in the absence of anti-HLA DSAs or Clustering approaches to identify novel phenotypes of kidney transplant rejection
Maarten Naesens, Belgium

Symposium 6.4
HISTOPATHOLOGY AND BEYOND IN RENAL TRANSPLANTATION
Chairs: Bruno Watschinger & Z. Serhan Tuglular

1. Determinants of early graft loss: what can we learn from histopathological findings?
Marlies Reinders, Netherlands

2. The importance of electron microscopy in diagnosing renal transplant rejection
Candice Roufosse, UK

3. MicroRNA and Chemokine Profiles in Urine to Identify renal transplant rejection
Michael Eikmans, Netherlands

MINI LECTURES

ML 6.1 TAILORING IMMUNOSUPPRESSION: LESSONS FROM THE IMMUNOLOGY LAB.
Annemarie Weissenbacher, Austria

ML 6.2 WHAT HAPPENED TO BELATACEPT
My Svensson, Norway

ML 6.3 WHEN OBESITY IS A PROBLEM IN KIDNEY TRANSPLANT CANDIDATES AND RECIPIENTS?
Alica Debska Slizien, Poland

ML 6.4 FERTILITY PROBLEMS IN KIDNEY TRANSPLANT RECIPIENTS MALE OB/GYN
Miroslaw Wielgos, Poland

ML 6.5 IS THERE A ROLE FOR SLGT2 INHIBITORS IN THE TREATMENT OF PTDM?
Trond Jenssen, Norway

ML 6.6 URINARY EXTRACELLULAR VESICLES: NEW USEFUL PROGNOSTIC MARKERS FOR KIDNEY TRANSPLANT.
Benedetta Bussolati, Italy

7 - HYPERTENSION, DIABETES, VASCULAR DISEASES

Symposium 7.1
HEART AND KIDNEY: AN INSIDIOUS RELATIONSHIP
Chairs: Beatriz Fernandez Fernandez & Mehmet Kanbay

1. Lung congestion in chronic kidney failure
Carmine Zoccali, Italy

2. The importance of screening and assessment of kidney function in patients with heart failure and DMT2
Martin De Borst, Netherlands

3. Uraemic Cardiomyopathy – is it truly reversible by transplantation?
Charles Ferro, UK

Symposium 7.2
CV COMPLICATIONS IN DIALYSIS
Chairs: My Svensson & Inga Arune Bumblyte

1. ABPM in CKD 5D: does surge BP matter for outcomes?
Olga Balafa, Greece

2. ABPM use in CKD patients: opportunities and challenges
Pantelis Sarafidis, Greece

4. CV risk assessment in dialysis patients. Does pre dialysis Blood pressure assessment really matter?
Angela Angela Wang, Hong Kong

Symposium 7.3
PHYSICAL ACTIVITIES IN CKD PATIENTS
Chairs: Jonathan Gabriel Fox & Sebastjan Bevc

1. Surveying Physical activity in CKD patients: what Nephrologists should know.
A Van Craenenbroeck, Belgium

2. Physical exercise in CKD patients: when and how is it feasible?
Naomi Clyne, Sweden

3. Assessment and management of obesity and metabolic syndrome in children with CKD and after kidney transplantation
Stella Stabouli, Greece

Symposium 7.4
A FAREWELL TO HYPERTENSIVE NEPHROSCLEROSIS
Chairs: Johannes F.E. Mann & Francesca Mallamaci

1. Hypertensive nephropathy: a major roadblock to precision nephrology
Sol Carriazo, Spain

2. Genetic phenocopies of hypertensive nephrosclerosis
Alice Doreille, France

3. APOL1 associated disease spectrum
waiting confirmation from the invited speaker

Symposium 7.5
HUMAN URINE AS THE WINDOW OF RENAL DISEASE.
Chairs: Robert Unwin & Katalin Suzstak

1. Non invasive biomarkers for Kidney fibrosis
Benjamin D Humphrey, USA

2. Urine markers for systemic sclerosis in CKD
Edward Stern, UK

3. The role of urinary ApoA-Ib in idiopati FSGS.
Conxita Jacobs-Cachá, Spain

MINI LECTURES

ML 7.1 OBESITY AS A HEALTH ISSUE: HOW COVID 19 PANDEMICS AMPLIFIED IT AS A SCARING RISK FACTOR.
Lucia Del Vecchio, Italy

ML 7.2 BODY COMPOSITION AND KIDNEY FUNCTION
Jung Tak Park, Korea

ML 7.3 MEDULLARY SPONGE KIDNEY AND RTA – A CHALLENGE AT THE NEPHROLOGY AND UROLOGY JUNCTION
Michael Straub, Munich, Germany

8 - ACUTE KIDNEY INJURY & INTENSIVE CARE NEPHROLOGY

Symposium 8.1
UPCOMING INNOVATIONS IN ACUTE KIDNEY INJURY
Chairs: Danilo Fliser & Christiane Erley

1. Deciphering the molecular mechanisms of necroinflammation in acute tubular necrosis
Wulf Tonnus, Germany

2. What is to come in the next KDIGO AKI guideline?
Marlies Ostermann, UK

3. Identifying patients at risk of the AKI-to-CKD transition
Morgan Grams, USA

Symposium 8.2
AKI-CKD TRANSITION – IS IT INEVITABLE?
Chairs: Marlies Ostermann & Michael Joannidis

1. Targeting the WnT pathway in AKI-CKD transition
Gewin LS, USA

2. Responses of the kidney to AKI in humans
Kai-Uwe Eckardt, Germany

3. Post AKI monitoring – how to recognize progressive CKD?
Vincenzo Cantaluppi, Italy

Symposium 8.3
CLINICAL ASPECTS OF AKI PREVENTION AND TREATMENT
Chairs: Claudio Ronco & Jolanta Malyszko

1. The second hit hypothesis – what should we look for?
Hoste EAJ, Belgium

2. Fluids in the ICU – which is the wright one?
Joannidis M, Austria

3. Identifying patients at high risk of in-hospital AKI
Catalina Martin-Cleary, Spain

Symposium 8.4
COVID, AKI AND BEYOND
Chairs: Nicholas Selby & Maria Prendecki

1. AKI during COVID-19 infection: specific or non specific renal injury?
Tobias Huber, Germany

2. Brain changes in nephroCovid19 patients
Davide Viggiano, Italy

3. Long-Covid and clinical implications
Bruchfeld Judith, Sweden

MINI LECTURES

ML 8.1 DEVELOPING AN AKI ALERT SYSTEM
Nicolas Selby, UK

ML 8.2 SGLT2 INHIBITORS AND AKI
Mehmet Kanbay, Turkey

ML 8.3 ONGOING AND RECENT CLINICAL TRIALS IN AKI
Stephane Gaudry, France

CME Courses

Discover an exciting educational activity which will be held on May 19, 2022, the first day of the 59th ERA Congress.

CME 1 - Primary & Secondary GN, vasculitis and autoimmune diseases

The Course will focus on current understanding and news in the field of immune-mediated kidney diseases and renal pathology. The lectures cover the progress in understanding of the pathogenesis, risk prediction for progression, novel treatment as well as long term complications of disease and treatment damage.

Chairs: Annette Bruchfeld, Kerstin Amann, Andreas Kronbichler

1. Technical Challenges to Discover Novel Antigens and Autoantibodies in Minimal Change Disease and Membranous Nephropathy
Astrid Weins, USA

2. Immunosuppressive Therapy in Patients with IgA Nephropathy revisited – clinical and histological aspects
Jürgen Floege, Germany

3. Repeat kidney biopsy as a biomarker in vasculitis and other GNs
Ingeborg Bajema, Netherlands

4. Hematologic Disorders and Kidney Disease
waiting confirmation from the invited speaker

5. Does Covid-19 or SARS-Cov-2 vaccine induce kidney disease?
waiting confirmation from the invited speaker

6. Comorbidities in ANCA-Associated Vasculitis
Andreas Kronbichler, UK

CME 2 - Hypertension, diabetes, cardiovascular diseases in CKD

This CME Course is a joint venture between the EURECAm and YNP working Groups. The topics of this Course aim to cover the most recent fields of interests for the nephrology community on Cardiovascular medicine. There will be two different sections, one for new diagnostic tools on cardiovascular disease screening in CKD population and another one focusing on treatments from the cardiologist and nephrologist point of view, with a final compendium of the strategies for achieving the best cardio renal results in patients with CKD.

Chairs: Beatriz Fernandez Fernandez, Pantelis Sarafidis, Amaryllis Van Craenenbroeck

part A:
1. cardiovascular risk screeningin CKD: biomarkers, cardiac MRI, cardiac US.
Patrick Mark, United Kingdom

2. Cardiovascularriskscreening in CKD: blood pressure monitoring.
George Stergiou, Greece

3. Cardiovascularriskscreening in CKD: endothelial function (methods) and arterial stiffness
Marietta Theodorakopoulou, Greece

part B- treatment:
1. HF with pEF in CKD : the cardiology perspective…
Nina Ajmone Marsan, Netherlands

2. HF with pEFIN CKD: the nephrology perspective.
Jolanta Malyszko, Poland

3. The role of lifestyle, exercise and rehabilitation in cardiorenal patient.
Sharlene Greenwood, United Kingdom

part C:
Achieving the best strategy for ESRD patients creating combined cardiorenal units.
Jose Luis Gorriz, Spain

CME 3 - CKD and bone mineral disorders in CKD

The syndrome of mineral and bone disorders remains an issue after kidney transplantation, despite the improvement in kidney function. Traditionally, substantial bone loss was expected in the early post-transplant period, with fracture risk increasing above that of patients remaining on dialysis. However, these well-known facts may need re-evaluation with the current steroid-sparing immunosuppressive protocols. Ongoing – and distinctive – disturbances of mineral metabolism prevail post-transplant; are these self-limiting, or potentially harmful? And what of cardiovascular risk; is it accentuated or attenuated after kidney transplantation? This session aims to deliver insights into the current state of CKD-MBD post-transplant, with expert opinions on how to manage cardiovascular risk and skeletal health in contemporary kidney transplant recipients.

Chairs: Hanne Skou Jorgensen, Sandro Mazzaferro, Jelmer Humalda

Introduction – setting the stage
Hanne Skou Jørgensen, DK

1. Bone loss in the era of steroid-sparing immunosuppressive protocols
Marie-Helene Lafage-Proust, France

2. Renal osteodystrophy post-transplant – lessons from bone biopsy studies
Nathalie Bravenboer, Netherlands

3. Mineral metabolism and acid-base disturbances
Jelmer Humalda, Netherlands

4. Optimizing cardiovascular health post-transplant
Marc Vervloet, Netherlands

5. Optimizing bone health post-transplant
Pieter Evenepoel, Belgium

Summary and concluding remarks
Sandro Mazzaferro, Italy

CME 4 - Haemo- and Peritoneal Dialysis

The aim of this year’s CME course in hemodialysis and peritoneal dialysis is to provide an update for practicing clinicians in key clinically important areas in dialysis, as well as areas in which there has been recent significant progress or clinical concern. The subjects selected for this year include: 1) The pathophysiology of peritoneal membrane function and preserving residual kidney function in dialysis patients 2) Technological aspects of dialysis including home and institutional dialysis 3) dialysis in emergency situations such as natural disasters or pandemics 4) adapting dialysis prescriptions for children and the elderly

Chairs: Rukshana Shroff, Mehmet Kanbay, Karlien Francois

Dialysis: physiology and pathology
1. Preserving residual kidney function in dialysis patients
Mehmet Kanbay, Turkey

2. Dialysis adequacy in PD and HD
Giorgina Piccoli, Italy

3. Understanding peritoneal membrane physiology – clinical implications
Johann Morelle, Switzerland

Round table discussion

Dialysis – technology
1. Renal replacement therapies in natural disasters and pandemics
Carlo Basile, Italy

2. Home or institutional haemodialysis?
Helena Rydell, Sweden

3. Is citrate-based dialysate the future?
Karlien François, Belgium

Round table discussion

Dialysis at the extremes of age
1. Pediatrics – what adult nephrologists should know about pediatric dialysis
Rukshana Shroff, UK

2. Geriatric patients – when to start dialysis and modality selection
Sandip Mitra, UK

Discussion

CME 5 - Kidney transplantation

The aim of this CME course is to provide an overview of the approach to kidney transplant recipients that experience graft loss. The specific questions addressed in these lectures should be relevant for the general nephrologist audience.

Chairs: M Crespo, C. Mariat, J. Callemeyn

1.Untangling the cause of transplant failure
Klemens Budde, Germany

2.Management of chronic kidney disease after transplantation
Anne-Elisabeth Heng, France

3.Immunosuppressive treatment after kidney transplant failure
María José Pérez-Sáez, Spain

4. Impact of sensitization and HLA matching on repeat transplantation
Aleksandar Senev, Belgium

5. Prognosis of the repeat transplantation
Umberto Maggiore, Italy

CME 6 - Acute Kidney Injury

AKI is a global concern and a common medical emergency encountered across all medica disciplines. This course will offer clinicians and clinical scientists’ new insights into the diagnosis and management of AKI and address questions that continue to come up every day at the bedside, including systemic organ dysfunctions in AKI, nutrition and nephrotoxicity of oncologic treatments.

Chairs: Valerie Luycks, Vincenzo Cantaluppi, Turgay Saritas

1. Novel diagnostic approaches in AKI: from urine analysis to machine learning
Eric Hoste, Belgium

2. Management of AKI- fluids, catecholamine, diuretics, ultrafiltration
Marlies Ostermann, King’s College, UK

3. Organ system crosstalk in AKI
Faeq Husain-Syed, Germany

4. Nutrition in AKI
Alice Sabatino, Italy

5. Nephrotoxicity of novel cancer drugs
Angel L M de Francisco, Spain

CME 7 - Electrolytes and urolithiasis

Electrolyte disorders and kidney stones are frequently encountered by nephrologists. This CEPD course will focus on the diagnostic and therapeutic approach to these disorders. New aspects and results from clinical trials, as well as emerging new therapies, will be discussed. The learning objectives of this course are to recognize underlying pathophysiological mechanisms, to understand their impact on kidney function, metabolic processes, and clinical outcomes, and to analyze and rationalize therapeutic options based on physiological principles.

Chairs: Olivier Bonny, Jean-Philippe Bertocchio, Ewout Hoorn

1. Hyponatremia: new diagnostic and therapeutic developments.
Mirjam Christ-Crain, Switzerland

2. Hypomagnesemia: from common causes to rare diseases.
Tom Nijenhuis, Netherlands

3. The return of an old friend: thiazide diuretics in CKD and kidney stones.
Daniel Fuster, Switzerland

4. Metabolic acidosis and citrate in CKD and kidney stones.
Sandrine Lemoine, France

5. Oxalate in nephrology: emerging roles and interventions.
Emmanuel Letavernier, France

CME 8 - Basics of Genetics for Nephrologists

This CME course aims to be a very basic and friendly course for nephrologists not experts in the field of hereditary kidney diseases. Aware that it is a relevant and quite unknown field in the world of nephrology, we intend to transmit a minimum knowledge to understand talks and articles on the subject, as well as being able to better address the management of these patients. We will try to clarify basic concepts of clinical genetics, we will give clues on how, when, and how to request a genetic study. And, in the most practical way possible, we will review the relevance of these diseases with concrete examples.

Chairs: Emilie Cornec Le Gal, Roser Torra Lucille Figueres

1. What should I know before ordering a genetic test?
Beata Lipska, Poland

2. Prescribing a genetic test: when, how, and what should be discussed with your patients before and after?
Emilie Cornec Le Gal, France

3. What are the reproductive options that can be offered?
Rozemarijn Snoek, Netherlands

4. How frequent are genetic diseases as cause of CKD?
Roser Torra, Spain

5. Making inherited tubulopathies easy
Lucille Figueres, France

6. Practical session about inherited kidney diseases
Daniel Gale, United Kingdom

Hands-on Courses

Discover an exciting educational activity which will be held on May 19, 2022, the first day of the 59th ERA Congress.

Ultrasound of arteriovenous fistula

Chairs: waiting confirmation from the invited chairs

1. Introduction
waiting confirmation from the invited speaker

2. How to examine a vascular access
waiting confirmation from the invited speaker

3 Selecting the best access by US mapping
waiting confirmation from the invited speaker

4. Non-maturing arteriovenous fistula
waiting confirmation from the invited speaker

5. Complication in vascular access
waiting confirmation from the invited speaker

Procedure / Virtual simulation
1. Virtual reality demo. From mapping to surveillance
waiting confirmation from the invited speaker

2. Vein mapping
waiting confirmation from the invited speaker

3. Stenosis
waiting confirmation from the invited speaker

4. Thrombosis
waiting confirmation from the invited speaker

5. Discussion
waiting confirmation from the invited speaker

Catheter placement

Chairs: waiting confirmation from the invited chairs

1. Introduction
waiting confirmation from the invited speaker

2. Central vein stenosis
waiting confirmation from the invited speaker

3. Fibrin sheath
waiting confirmation from the invited speaker

4. Kinking and tip position
waiting confirmation from the invited speaker

5. Atrial thrombus
waiting confirmation from the invited speaker

Procedure / Virtual simulation
1. Virtual realiy demo. Anatomical approach for ultrasound guided cannulation
waiting confirmation from the invited speaker

2. Non-tunnelled line insertion
waiting confirmation from the invited speaker

3. Tunnelled line insertion
waiting confirmation from the invited speaker

4. Discussion

Renal Biopsy

Chairs: waiting confirmation from the invited chairs

1. Introduction
waiting confirmation from the invited speaker

2. Indications and epidemiology of native kidney biopsy
waiting confirmation from the invited speaker

3 Practical aspect of Biopsy
waiting confirmation from the invited speaker

4. Practical pathology for Biopsy (Processing of the samples and tests)
waiting confirmation from the invited speaker

5. Complications of Kidney Biopsy
waiting confirmation from the invited speaker

Q&A and Discussion

Procedure / Virtual simulation
1. US demonstration
waiting confirmation from the invited speaker

2. US practice
waiting confirmation from the invited speaker

3. Biopsy demonstration on model
waiting confirmation from the invited speaker

4. Biopsy practice
waiting confirmation from the invited speaker

5. Concluding remarks
waiting confirmation from the invited speaker